Endo sells its international pharmaceuticals business
Torys acted as counsel to Endo and Paladin with a team led by Konata Lake and that included Yasmine Mekallach (corporate/M&A), Omar Wakil and Ian Li (competition), Teresa Reguly and Yu Seon Gadsden-Chung (life sciences regulatory).
On June 17, 2025, Endo, Inc. (“Endo”) announced that it completed the previously announced definitive agreement, dated March 11, 2025, to divest its international pharmaceuticals business, primarily operated through Paladin Pharma Inc. (“Paladin”), to Knight Therapeutics Inc. (“Knight Therapeutics”) for a total consideration of up to US$105 million. The consideration consists of approximately US$79 million paid at closing and up to an additional US$15 million in potential future payments contingent upon the achievement of certain milestones.
Further information can be found on PR Newswire’s website.
Paladin is a leading specialty pharmaceutical company focused on acquiring or licensing emerging pharmaceuticals for the Canadian market.
Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies.